Thomas Peppard

Thomas Peppard

Auto-generated profile, based on publicly available information

Thomas Peppard

Certara, LP, on contract to the Bill and Melinda Gates Foundation, Greater Detroit Area, United States of America

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2012 in The Journal of Clinical Hypertension
Verified
Journal Article
Closed access
PDF file
AKAdam D. Karns
Adam D. Karns
JBJacqueline M. Bral
Jacqueline M. Bral
DHDaniel Hartman
Daniel Hartman
TPThomas Peppard
Thomas Peppard
CSChristoph Schumacher
Christoph Schumacher

7 June 2012 in The Journal of Clinical Hypertension
Verified
Journal Article
Closed access
PDF file
KAKarl Andersen
Karl Andersen
DHDaniel Hartman
Daniel Hartman
TPThomas Peppard
Thomas Peppard
DHDavid Hermann
David Hermann
PEPeter Van Ess
Peter Van Ess
ATAngelo Trapani
Angelo Trapani

29 April 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RWRobert S. Wallis
Robert S. Wallis
TPThomas Peppard
Thomas Peppard
DHDavid Hermann
David Hermann
New regimens capable of shortening tuberculosis treatment without increasing the risk of recurrence are urgently needed. A 2013 meta-regression analysis, using data from trials published from 1973 to 1997 involving 7793 patients, identified 2-month sputum culture status and treatment duration as independent predictors of recurrence. The resulting model predicted that if a new 4-month regimen reduced the proportion of patients positive at month 2 to 1%, it would reduce to 10% the risk of a relapse rate >10% in a trial with 680 subjects per arm. The 1% target was far lower than anticipated. Data from the 8 arms of 3 recent unsuccessful phase 3 treatment-shortening trials of fluoroquinolone-substituted regimens (REMox, OFLOTUB, and RIFAQUIN) were used to assess and refine the accuracy of the 2013 meta-regression model. The updated model was then tested using data from a treatment shortening trial reported in 2009 by Johnson et al. The proportions of patients with recurrence as predicted by the 2013 model were highly correlated with observed proportions as reported in the literature (R2 = 0.86). Using the previously proposed threshold of 10% recurrences as the maximum likely considered acceptable by tuberculosis control programs, the original model correctly identified all 4 six-month regimens as satisfactory, and 3 of 4 four-month regimens as unsatisfactory (sensitivity = 100%, specificity = 75%, PPV = 80%, and NPV = 100%). A revision of the regression model based on the full dataset of 66 regimens and 11181 patients resulted in only minimal changes to its predictions. A test of the revised model using data from the treatment shortening trial of Johnson et al found the reported relapse rates in both arms to be consistent with predictions. Meta-regression modeling of recurrence based on month 2 culture status and regimen duration can inform the design of future phase 3 tuberculosis clinical trials.

10 August 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SSShubhada Shenai
Shubhada Shenai
KRKatharina Ronacher
Katharina Ronacher
SMStefanus Malherbe
Stefanus Malherbe
KSKim Stanley
Kim Stanley
MKMagdalena Kriel
Magdalena Kriel
DADavid Alland
David Alland
Biomarkers are needed to monitor tuberculosis (TB) treatment and predict treatment outcomes. We evaluated the Xpert MTB/RIF (Xpert) assay as a biomarker for TB treatment during and at the end of the 24 weeks therapy. Sputum from 108 HIV-negative, culture-positive pulmonary TB patients was analyzed using Xpert at time points before and during anti-TB therapy. Results were compared against culture. Direct Xpert cycle-threshold (Ct), a change in the Ct (delta Ct), or a novel “percent closing of baseline Ct deficit” (percent closing) were evaluated as classifiers of same-day and end-of-treatment culture and therapeutic outcomes. Xpert was positive in 29/95 (30.5%) of subjects at week 24; and positive one year after treatment in 8/64 (12.5%) successfully-treated patients who remained free of tuberculosis. We identified a relationship between initial bacterial load measured by baseline Xpert Ct and time to culture conversion (hazard ratio 1.06, p = 0.0023), and to the likelihood of being among the 8 treatment failures at week 24 (AUC = 72.8%). Xpert Ct was even more strongly associated with culture conversion on the day the test was performed with AUCs 96.7%, 99.2%, 86.0% and 90.2%, at Day 7, Week 4, 8 and 24, respectively. Compared to baseline Ct measures alone, a combined measure of baseline Ct plus either Delta Ct or percent closing improved the classification of treatment failure status to a 75% sensitivity and 88.9% specificity. Genome loads measured by Xpert provide a potentially-useful biomarker for classifying same day culture status and predicting response to therapy.